Is Ancient Medical Treatment an Option for Curating Osteosarcoma Combined with Chemotherapy? A Basic Analysis of Clinic Pharmacy


如何引用文章

全文:

详细

Background::As a malignant tumor, osteosarcoma (OS) ranks first place among adolescent cancers and is susceptible to developing resistance to chemotherapeutic agents. Differently, traditional Chinese medicine (TCM) has multiple pharmacodynamic targets and complex biological components, which can inhibit tumor survival and drug resistance and gradually play an important role in the treatment of sarcoma.

Methods::This study is to systematically evaluate the safety and efficacy of TCM combined with chemotherapy performed in the clinical treatment of OS. Based on multiple mainstream databases, eleven articles on the relationship between natural products and chemotherapy involving 656 patients were selected from all the literature published as of June 2022. Revman 5.4 software was used for a comprehensive search analysis, supplemented by established exclusion criteria, the Jadad scale, and the evaluation methods provided by Cochrane.

Results::The efficiency of TCM combined with chemotherapy was significantly increased compared with chemical drugs alone [OR=2.56, 95% CI (1.36,4.79), Z=2.92, P=0.003]. Meanwhile, the adverse reactions such as nausea and vomiting, hepatotoxicity, and hematological changes caused by chemical drugs were alleviated correspondingly.

Conclusion::This study indicates that the mode of TCM combined with chemotherapy sheds light on the clinical treatment of OS, which is much better than the one-way mode.

作者简介

Jian-yu Hu

, Dalian Municipal Central Hospital Affiliated of Dalian University of Technology

Email: info@benthamscience.net

Ya-ru Gao

School of Life and Pharmaceutical Sciences, Dalian University of Technology

Email: info@benthamscience.net

Yu-qi Bao

School of Life and Pharmaceutical Sciences, Dalian University of Technology

Email: info@benthamscience.net

Jing Zhao

School of Life and Pharmaceutical Sciences, Dalian University of Technology

Email: info@benthamscience.net

Bo Liu

School of Life and Pharmaceutical Sciences, Dalian University of Technology

Email: info@benthamscience.net

Chang-wei Zhao

, Affiliated Hospital of Changchun University of Traditional Chinese Medicine

编辑信件的主要联系方式.
Email: info@benthamscience.net

Zheng-yao Zhang

School of Life and Pharmaceutical Sciences, Dalian University of Technology

编辑信件的主要联系方式.
Email: info@benthamscience.net

参考

  1. Ritter, J.; Bielack, S.S. Osteosarcoma. Ann. Oncol., 2010, 21(S7), vii320-vii325. doi: 10.1093/annonc/mdq276 PMID: 20943636
  2. Corre, I.; Verrecchia, F.; Crenn, V.; Redini, F.; Trichet, V. The osteosarcoma microenvironment: A complex but targetable ecosystem. Cells, 2020, 9(4), 976. doi: 10.3390/cells9040976 PMID: 32326444
  3. Brown, H.K.; Tellez-Gabriel, M.; Heymann, D. Cancer stem cells in osteosarcoma. Cancer Lett., 2017, 386, 189-195. doi: 10.1016/j.canlet.2016.11.019 PMID: 27894960
  4. Rothzerg, E.; Ingley, E.; Mullin, B.; Xue, W.; Wood, D.; Xu, J. The Hippo in the room: Targeting the Hippo signalling pathway for osteosarcoma therapies. J. Cell. Physiol., 2021, 236(3), 1606-1615. doi: 10.1002/jcp.29967 PMID: 32697358
  5. Messerschmitt, P.J.; Garcia, R.M.; Abdul-Karim, F.W.; Greenfield, E.M.; Getty, P.J. Osteosarcoma. J. Am. Acad. Orthop. Surg., 2009, 17(8), 515-527. doi: 10.5435/00124635-200908000-00005 PMID: 19652033
  6. Farfalli, G.L.; Albergo, J.I.; Lobos, P.A.; Smith, D.E.; Streitenberger, P.D.; Pallotta Rodríguez, M.G.; Aponte-Tinao, L.A. Osteosarcoma lung metastases. Survival after chemotherapy and surgery. Medicina, 2015, 75(2), 87-90. PMID: 25919869
  7. Cersosimo, F.; Lonardi, S.; Bernardini, G.; Telfer, B.; Mandelli, G.E.; Santucci, A.; Vermi, W.; Giurisato, E. Tumor-associated macrophages in osteosarcoma: From mechanisms to therapy. Int. J. Mol. Sci., 2020, 21(15), 5207. doi: 10.3390/ijms21155207 PMID: 32717819
  8. Yang, C.; Tian, Y.; Zhao, F.; Chen, Z.; Su, P.; Li, Y.; Qian, A. Bone microenvironment and osteosarcoma metastasis. Int. J. Mol. Sci., 2020, 21(19), 6985. doi: 10.3390/ijms21196985 PMID: 32977425
  9. Isakoff, M.S.; Bielack, S.S.; Meltzer, P.; Gorlick, R. Osteosarcoma: Current treatment and a collaborative pathway to success. J. Clin. Oncol., 2015, 33(27), 3029-3035. doi: 10.1200/JCO.2014.59.4895 PMID: 26304877
  10. Tan, M.L.; Choong, P.F.M.; Dass, C.R. Osteosarcoma – conventional treatment vs. gene therapy. Cancer Biol. Ther., 2009, 8(2), 106-117. doi: 10.4161/cbt.8.2.7385 PMID: 19098456
  11. Xia, X.Z.; Yu, D.D.; Li, X. Research progress of osteosarcoma treated with traditional chinese medicine. Yunnan J. Tradit Chin Med Materia Medica, 2021, 42(11), 83-87.
  12. Zhou, N.N.; Fag, B.; Yi, C.Z. Research progress of osteosarcoma treated with traditional chinese medicine. Chin. Clin. Oncol., 2021, 3(01), 76-81.
  13. Fan, L.J.; Ma, Y.; Luo, Y.G. Advances in chinese medicine treatment of osteosarcoma. Chin. J. Convalescent. Med., 2022, 2022
  14. Zhang, Y.; Yang, J.; Zhao, N.; Wang, C.; Kamar, S.; Zhou, Y.; He, Z.; Yang, J.; Sun, B.; Shi, X.; Han, L.; Yang, Z. Progress in the chemotherapeutic treatment of osteosarcoma (Review).. Oncol. Lett., 2018, 16(5), 6228-6237. doi: 10.3892/ol.2018.9434 PMID: 30405759
  15. Pu, F.F.; Shao, Z.W. Advances in osteosarcoma gene therapy research. Int. J. Orthop. (Hong Kong), 2013.
  16. Cai, L. Current status and prospects of targeted therapy for osteosarcoma. Cells, 2022, 11(21), 3507.
  17. Xiong, J.; Xu, J.; Luo, D.S. 32 cases of malignant bone tumors treated with Shenmai Decoction. NJUCM, 2001, (05), 325.
  18. Gu, J.L.; Li, D.S.; Du, Z.Q. 27 cases of osteosarcoma treated with Huyan capsule. Shaanxi J. Trad. Chin. Med., 2002, (12), 1081-1082.
  19. Kuang, T.H.; Liu, Y.X. Application of ShenQiFuZheng injection with large dose neoadjuvent chemotherapy in 30 cases with osteosarcoma. J. Clin. Oncol., 2009, 15(05), 473-474.
  20. Cheng, X.R. 19 cases of osteosarcoma treated with Chinese medicine combined with chemotherapy. Henan Trad. Chin. Med., 2011, 31(01), 51-52.
  21. Jiang, S.J.; Liu, Y.X.; Yang, J.W. Efficacy of self-designed Chai Hu Chui Pen Decoction in preventing liver injury in 43 cases of osteosarcoma chemotherapy. Zhejiang. J. Tradit. Chin. Med., 2012, 47(04), 266.
  22. Zhang, L.L.; Yang, L.; Zhang, Q. Effects of TCM emotion nursing on osteosarcoma patients treated with methotrexate. Anti-Tumor Pharmacy, 2018, 8(04), 653-656.
  23. Jiang, Y.; Niu, X.H.; Gao, Y.M. 30 cases of classic osteosarcoma treated with compound cantharides capsules combined with chemotherapy. Chin. J. Trad. Med. Traumatol. Orthoped., 2020, 28(02), 63-65.
  24. Wu, L.W. Adjuvant efficacy of Danggui Buxue Decoction in the prevention and treatment of bone marrow suppression caused by chemotherapy in patients with primary malignant bone tumors; Fujian University of Chinese Medicine, 2020.
  25. Zhao, L.N.; Tian, X.Y. Analysis of TCM syndrome differentiation for treatment of bone and soft tissue sarcoma. Smart Healthcare, 2020, 6(5), 114-115,120.
  26. Yunxia, Liu; Yun, Ye; Guanqun, Xie; Yefeng, Xu; Miao, Cheng; Chunling, Li; Mengqi, Qu; Feiye, Zhu Pharmacological Mechanism of Sancao Yuyang Decoction in the Treatment of Oral Mucositis Based on Network Pharmacology and Experimental Validation. Drug Des. Devel. Ther., 2023, 17(2023), 55-74. doi: 10.2147/DDDT.S391978
  27. Zhu, X.; Wu, C.Y.; Lin, J.H. Clinical observation on the treatment of drug-resistant osteosarcoma with adjuvant chemotherapy with elemicin. Guangming J. Chin. Med., 2011, 26(10), 2091-2092.
  28. Manuel , A. Riquelme; Eduardo, R. Cardenas; Jean, X. Jiang Osteocytes and Bone Metastasis. Front. Endocrinol., 2020, 11(2020), 567844. doi: 10.3389/fendo.2020.567844
  29. Niu, X.H. Interpretation of 2020 NCCN clinical practice guidelines in oncology-bone cancer. Zhonghua Wai Ke Za Zhi, 2020, 58(6), 430-434. PMID: 32498481
  30. Kciuk, M.; Gielecińska, A.; Mujwar, S.; Kołat, D.; Kałuzińska-Kołat, Ż.; Celik, I.; Kontek, R. Doxorubicin—an agent with multiple mechanisms of anticancer activity. Cells, 2023, 12(4), 659. doi: 10.3390/cells12040659 PMID: 36831326
  31. Wei, H.; Chen, F.; Chen, J.; Lin, H.; Wang, S.; Wang, Y.; Wu, C.; Lin, J.; Zhong, G. Mesenchymal stem cell derived exosomes as nanodrug carrier of doxorubicin for targeted osteosarcoma therapy via SDF1-CXCR4 axis. Int. J. Nanomedicine, 2022, 17, 3483-3495. doi: 10.2147/IJN.S372851 PMID: 35959282
  32. Bielack, S.S.; Smeland, S.; Whelan, J.S.; Marina, N.; Jovic, G.; Hook, J.M.; Krailo, M.D.; Gebhardt, M.; Pápai, Z.; Meyer, J.; Nadel, H.; Randall, R.L.; Deffenbaugh, C.; Nagarajan, R.; Brennan, B.; Letson, G.D.; Teot, L.A.; Goorin, A.; Baumhoer, D.; Kager, L.; Werner, M.; Lau, C.C.; Sundby Hall, K.; Gelderblom, H.; Meyers, P.; Gorlick, R.; Windhager, R.; Helmke, K.; Eriksson, M.; Hoogerbrugge, P.M.; Schomberg, P.; Tunn, P.U.; Kühne, T.; Jürgens, H.; van den Berg, H.; Böhling, T.; Picton, S.; Renard, M.; Reichardt, P.; Gerss, J.; Butterfass-Bahloul, T.; Morris, C.; Hogendoorn, P.C.W.; Seddon, B.; Calaminus, G.; Michelagnoli, M.; Dhooge, C.; Sydes, M.R.; Bernstein, M. Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b >versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomized controlled trial. J. Clin. Oncol., 2015, 33(20), 2279-2287. doi: 10.1200/JCO.2014.60.0734 PMID: 26033801
  33. Li, C.; Liu, X.; Zhang, L.; Chen, L.; Shi, X.; Wu, S.; Zhao, J. Advances in bone‐targeted drug delivery systems for neoadjuvant chemotherapy for osteosarcoma. Orthop. Surg., 2016, 8(2), 105-110. doi: 10.1111/os.12238 PMID: 27384718
  34. Yamamoto, N.; Tsuchiya, H. Chemotherapy for osteosarcoma – Where does it come from? What is it? Where is it going? Expert Opin. Pharmacother., 2013, 14(16), 2183-2193. doi: 10.1517/14656566.2013.827171 PMID: 23919484
  35. Niu, X.H.; Xu, H.R. Advances in chemotherapy for osteosarcoma. China Oncology, 2012, 22(09), 663-668.
  36. Wang, H.; Sun, G.Z. Sun Guizhi’s experience in treating osteosarcoma. World Chin. Med., 2012, 7(01), 21-22.
  37. Tay, K.C.; Tan, L.T.H.; Chan, C.K.; Hong, S.L.; Chan, K.G.; Yap, W.H.; Pusparajah, P.; Lee, L.H.; Goh, B.H. Formononetin: A review of its anticancer potentials and mechanisms. Front. Pharmacol., 2019, 10, 820. doi: 10.3389/fphar.2019.00820 PMID: 31402861
  38. Liu, H.; Zhu, Y.; Zhang, T.; Zhao, Z.; Zhao, Y.; Cheng, P.; Li, H.; Gao, H.; Su, X. Anti-tumor effects of atractylenolide I isolated from Atractylodes macrocephala in human lung carcinoma cell lines. Molecules, 2013, 18(11), 13357-13368. doi: 10.3390/molecules181113357 PMID: 24172243
  39. Chen, M.; Li, Y.; Liu, Z.; Qu, Y.; Zhang, H.; Li, D.; Zhou, J.; Xie, S.; Liu, M. Exopolysaccharides from a Codonopsis pilosula endophyte activate macrophages and inhibit cancer cell proliferation and migration. Thorac. Cancer, 2018, 9(5), 630-639. doi: 10.1111/1759-7714.12630 PMID: 29577649
  40. Li, P.F.; Duan, K.; Zou, Z.L. Treatment of osteosarcoma from invigorating spleen and tonifying kidney. Dazhong Keji, 2018, 20(11), 41-43.
  41. Liu, Y.L.; Yin, C.C.; Zhang, Y.P. Mechanism of anti-osteosarcoma of icaritin. Zhongchengyao, 2014, 36(01), 4-9.
  42. Xiangyong, Y.; Zhongsheng, Y.; Wenchao, L.; Hui, D.; Shuzhou, Q.; Gang, C. XiaoHui, W.; Lian, Z. External application of traditional Chinese medicine in the treatment of bone cancer pain: A meta-analysis. Support. Care Cancer, 2016, 24(1), 11-17. doi: 10.1007/s00520-015-2737-2 PMID: 25894886

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bentham Science Publishers, 2024